Evidence map›Paper›PMID 25783759›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2015

Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates.

H Zhang, H Guo, L Lu, A F Zahorchak, R W Wiseman, G Raimondi, D K C Cooper, M B Ezzelarab, A W Thomson

Open access · bronzeAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Genetically engineered porcine liver: a new era in transplantation.International journal of surgery (London, England) · 2026
    Article
  2. Review
  3. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. The Pursuit of Regulatory T Cells in the Induction of Transplant Tolerance.Advances in experimental medicine and biology · 2021
    Article
  9. Combined GM-CSF and G-CSF administration mobilizes CD4American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  10. Article
  11. Review
  12. Review
  13. IL-2 therapy preferentially expands adoptively transferred donor-specific Tregs improving skin allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Article
  14. Methods to manufacture regulatory T cells for cell therapy.Clinical and experimental immunology · 2019
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Transplant trials with Tregs: perils and promises.The Journal of clinical investigation · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

H ZhangThomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.
H Guo
L Lu
A F Zahorchak
R W Wiseman
G Raimondi
D K C Cooper
M B Ezzelarab
A W Thomson
University of Pittsburgh · USUniversity of Wisconsin–Madison · US

Funding

Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in MonkeysU01AI091197 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2010 to 2016
$4.3M
Interdisciplinary Training in Transplantation BiologyT32AI074490 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Angus W Thomson · 2007 to 2026
$4.2M
NIAID NIH HHS HHSN272201100013CNIAID NIH HHS HHSN272201100013INIAID NIH HHS T32 AI074490NIAID NIH HHS U01 AI091197NIAID NIH HHS U01 AI91197PHS HHS HHSN272201100013C
6 · The paper itself

Abstract

Ex vivo-expanded cynomolgus monkey CD4(+)CD25(+)CD127(-) regulatory T cells (Treg) maintained Foxp3 demethylation status at the Treg-specific demethylation region, and potently suppressed T cell proliferation through three rounds of expansion. When carboxyfluorescein succinimidyl ester- or violet proliferation dye 450-labeled autologous (auto) and nonautologous (non-auto)-expanded Treg were infused into monkeys, the number of labeled auto-Treg in peripheral blood declined rapidly during the first week, but persisted at low levels in both normal and anti-thymocyte globulin plus rapamycin-treated (immunosuppressed; IS) animals for at least 3 weeks. By contrast, MHC-mismatched non-auto-Treg could not be detected in normal monkey blood or in blood of two out of the three IS monkeys by day 6 postinfusion. They were also more difficult to detect than auto-Treg in peripheral lymphoid tissue. Both auto- and non-auto-Treg maintained Ki67 expression early after infusion. Sequential monitoring revealed that adoptively transferred auto-Treg maintained similarly high levels of Foxp3 and CD25 and low CD127 compared with endogenous Treg, although Foxp3 staining diminished over time in these nontransplanted recipients. Thus, infused ex vivo-expanded auto-Treg persist longer than MHC-mismatched non-auto-Treg in blood of nonhuman primates and can be detected in secondary lymphoid tissue. Host lymphodepletion and rapamycin administration did not consistently prolong the persistence of non-auto-Treg in these sites.

Indexed as

AnimalsAntilymphocyte SerumForkhead Transcription FactorsHaplotypesImmunosuppressive AgentsInterleukin-2 Receptor alpha SubunitInterleukin-7 Receptor alpha SubunitKi-67 AntigenMacaca fascicularisMajor Histocompatibility ComplexMaleMethylationPhenotypeSirolimusT-Lymphocytes, RegulatoryAntilymphocyte SerumForkhead Transcription FactorsImmunosuppressive AgentsInterleukin-2 Receptor alpha SubunitInterleukin-7 Receptor alpha SubunitKi-67 AntigenSirolimusanimal models: nonhuman primatebasic (laboratory) research / scienceimmunobiologyimmunosuppressantImmunosuppressantimmunosuppression / immune modulationmechanistic target of rapamycin (mTOR)polyclonal preparations: rabbit antithymocyte globulinT cell biologytranslational research / science

Identifiers

PMID25783759
PMCPMC4773915
OpenAlexW1557503054

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.